ANP – Antisense Therapeutics Ltd

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Recommendation Rating

2

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 0.21

Low: 0.17

High: 0.24

Total Analysts: 2

Company Profile

Antisense Therapeutics Limited is an Australia-based biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for unmet markets in rare diseases. The Company’s product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly. The Company’s product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The Company completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The Company is engaged in clinical development of ATL1102 in patients with Duchenne Muscular Dystrophy (DMD). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Responses